BMS’ Opdivo cleared for monthly use
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bms_opdivo_cleared_for_monthly_use_1226100